AXA Framlington Biotech R

Quick Stats

Bid Price - Offer Price -
Mid Price USX 93.56 Day Change USX +-0.57 (0.01%)
Price Date 25 Oct 2016 Crown Rating 1
Shares Class Inc. Yield 0.00 %
Total Expense Ratio 0.00 Fund Size 535,883,200.00
Launch Date 26/11/2001 Standard Initial Charge (%) 0.00
Currency USX ISA Eligible No
Annual Management Charge (%) 0.00 Sector IMA UK Equity Income
Min Investment (£) 0.00 Total Expense Ratio (%) 0.00
ISIN Min TopUp (£) 0.00

Fund Objective

The aim of this Fund is to provide long-term capital growth.

Fund Managers

Linden Thomson
Linden Thomson joined AXA IM in June 2011 as sector specialist on the Healthcare equity desk. Linden joined AXA IM from Hedge Fund Clear River Capital where she was responsible for fundamental stock research across the global pharmaceutical and biotechnology sectors. Prior to that she worked for Goldman Sachs on the sell side where she was based in the healthcare research team with specific focus on the biotechnology sector. She graduated from Edinburgh University with a BSc in Medical Microbiology and is a CFA Charterholder.